GlassScriptPhysician profile
Traci J King
NPI 1427671346
$919.93
in general payments reported to CMS, 2019-2025
10 companies · $753 in 2025
The $753 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $167 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $919.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $292.51 | 2025 | Darzalex, Tecvayli, Carvykti |
| Daiichi Sankyo INC. | $195.07 | 2024-2025 | Datroway, Enhertu |
| Pfizer INC. | $95.02 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $85.39 | 2024-2025 | Enhertu |
| Genzyme Corporation | $77.80 | 2025 | |
| Novartis Pharmaceuticals Corporation | $71.80 | 2025 | |
| Beone Medicines USA, INC. | $33.56 | 2025 | Tevimbra |
| Adaptive Biotechnologies Corporation | $29.60 | 2024 | Clonoseq |
| Tersera Therapeutics LLC | $25.06 | 2025 | Zoladex |
| Gilead Sciences, INC. | $14.12 | 2025 | Trodelvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Traci King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.